Ingredient Transparency
At XOVVA, clinical efficacy is driven by molecular precision. We disclose the exact active compounds, delivery mechanisms, and rigorous scientific rationale behind every formulation in our TONEVA and TRICHOVVA protocols.
Primary Active Compounds
Liposomal Azelaic Acid
Clinical Role
Tyrosinase inhibitor and anti-inflammatory agent targeting post-inflammatory hyperpigmentation and melasma.
Mechanism of Action
Competitively inhibits tyrosinase in vitro, decreasing melanin synthesis in highly active melanocytes without affecting normal skin pigment.
Tranexamic Acid
Clinical Role
Plasmin inhibitor preventing UV-induced pigmentation and vascular-driven erythema.
Mechanism of Action
Blocks the interaction of melanocytes and keratinocytes by inhibiting plasminogen binding to the keratinocyte surface, reducing arachidonic acid and prostaglandins.
Wnt/β-catenin Peptides
Clinical Role
Follicular stem cell activator to prolong anagen phase and stimulate dermal papilla cells.
Mechanism of Action
Upregulates Wnt10b expression in the dermal papilla, triggering the β-catenin signaling cascade essential for hair follicle neogenesis and cycling.